Optimal periprocedural antithrombotic therapy in percutaneous coronary intervention: Between a rock and a hard place?
The identification of the optimal periprocedural antithrombotic therapy for percutaneous coronary interventions is still a matter of debate [1,2]. On the one hand percutaneous coronary intervention per se induces thrombin generation which makes necessary administration of adjunctive antithrombotic therapy [1,2], on the other hand bleeding complications can significantly influence acute- and long-term survival and morbidity [3]. The ideal antithrombotic medication should have rapid onset of action, predictable dose-dependent effect, quick reversibility, and wide therapeutic window.
Source: Cardiovascular Revascularization Medicine - Category: Cardiology Authors: Daniele Giacoppo, Adnan Kastrati Tags: Editorials Source Type: research
More News: Angioplasty | Bleeding | Cardiology | Cardiovascular | Coronary Angioplasty | Heart | Percutaneous Coronary Intervention